MDACC Study No:ID03-0172 ( NCT No: NCT00082719)
Title:Modulation of Death Effector Expression By Short-Term Exposure to Low-Dose Interferon
Principal Investigator:Ashish M. Kamat
Treatment Agent:Interferon Alpha-2B
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn what effects (if any)
interferon has on bladder cancer tissue.
Hide details for General InformationGeneral Information

Disease Group:Bladder
Phase of Study:Phase I
Treatment Agents:Interferon Alpha-2B
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:one visit, 23 hour observation
Supported By:N/A
Return Visit:No additional visits required by the protocol, other than those dictated by the
treatment of their cancer.
Home Care:The interferon could be self-administered or administered in the Urology
Clinic. Tylenol 650mg by mouth 30 minutes prior to injection and every 4 hours
as necessary.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Ashish M. Kamat
For Clinical Trial Enrollment:713-792-3250
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults